The global incidence of diabetes is rising steadily and with it the number of people living with diabetic retinal disease (DRD) is increasing. Like diabetes, DRD can be treated but not cured. In response, therapies to address DRD include targeted ocular and systemic medications. This review discusses diabetes and DRD in terms of current screening recommendations, treatments, and considerations related to those therapies and future drug targets and trials on the horizon. This discourse is targeted at all members of the diabetes care team, including primary care providers, optometrists, and ophthalmologists. The dynamic landscape of diabetic retinopathy treatment is promising for the prevention and improvement of visually significant disease.
Get full access to this article
View all access options for this article.
References
1.
SunH, SaeediP, KarurangaS, et al.IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Research and Clinical Practice, 2022; 183:109119.
2.
ChaAE, VillarroelMA, VahratianA. Eye disorders and vision loss among US adults aged 45 and over with diagnosed diabetes, 2016–2017. NCHS Data Brief, 2019(344):1–8.
3.
OgurtsovaK, da Rocha FernandesJD, HuangY, et al.IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract, 2017; 128:40–50.
4.
SabanayagamC, BanuR, CheeML, et al.Incidence and progression of diabetic retinopathy: A systematic review. Lancet Diabetes Endocrinol, 2019; 7(2):140–149.
5.
CheungN, WongTY. Diabetic retinopathy and systemic complications. Diabetic Retinopathy, 2008:465–482.
6.
YauJWY, RogersSL, KawasakiR, et al.Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care, 2012; 35(3):556–564.
7.
KleinR, LeeKE, GangnonRE, KleinBE. The 25-year incidence of visual impairment in type 1 diabetes mellitus: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology, 2010; 117(1):63–70.
8.
TomicD, ShawJE, MaglianoDJ. The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol, 2022; 18(9):525–539.
9.
SloanG, SelvarajahD, TesfayeS. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nat Rev Endocrinol, 2021; 17(7):400–420.
10.
LechnerJ, O’LearyOE, StittAW. The pathology associated with diabetic retinopathy. Vision Res, 2017; 139:7–14.
LorenziM. The polyol pathway as a mechanism for diabetic retinopathy: Attractive, elusive, and resilient. Exp Diabetes Res, 2007; 2007:61038.
13.
KandarakisSA, PiperiC, TopouzisF, et al.Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases. Prog Retin Eye Res, 2014; 42:85–102.
14.
DuhEJ, SunJK, StittAW. Diabetic retinopathy: Current understanding, mechanisms, and treatment strategies. JCI Insight, 2017; 2(14).
15.
HartnettME, FickweilerW, AdamisAP, et al.Rationale of basic and cellular mechanisms considered in updating the staging system for diabetic retinal disease. Ophthalmol Sci, 2024; 4(5):100521.
GangeWS, LopezJ, XuBY, et al.Incidence of proliferative diabetic retinopathy and other neovascular sequelae at 5 years following diagnosis of type 2 diabetes. Diabetes Care, 2021; 44(11):2518–2526.
18.
WongTY, TanT-E. The diabetic retinopathy “pandemic” and evolving global strategies: The 2023 Friedenwald lecture. Invest Ophthalmol Vis Sci, 2023; 64(15):47–47.
19.
SilvaPS, CavalleranoJD, SunJK, et al.Disparities Between teleretinal imaging findings and patient-reported diabetic retinopathy status and follow-up eye care interval: A 10-Year Prospective Study. Diabetes Care, 2024; 47(6):970–977.
20.
KonstantinidisL, CarronT, de AncosE, et al.Awareness and practices regarding eye diseases among patients with diabetes: A cross sectional analysis of the CoDiab-VD cohort. BMC Endocr Disord, 2017; 17(1):56–11.
21.
Committee ADAPP. 12. Retinopathy, neuropathy, and foot care: Standards of care in diabetes—2024. Diabetes Care, 2024; 47:S231–S243.
22.
FlaxelCJ, AdelmanRA, BaileyST, et al.Diabetic retinopathy preferred practice pattern®. Ophthalmology, 2020; 127(1):P66–P145.
23.
ArcaduF, BenmansourF, MaunzA, et al.Deep learning algorithm predicts diabetic retinopathy progression in individual patients. NPJ Digit Med, 2019; 2:92.
24.
Group ETDRSR. Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS report number 12. Ophthalmology, 1991; 98:823–833.
25.
KleinR, KleinBE, MossSE, et al.The Wisconsin epidemiologic study of diabetic retinopathy: IV. Diabetic macular edema. Ophthalmology, 1984; 91(12):1464–1474.
26.
Group ETDRSR. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology, 1991; 98:766–785.
27.
XuX, ZhangM, HuangS, et al.The application of artificial intelligence in diabetic retinopathy: Progress and prospects. Front Cell Dev Biol, 2024; 12:1473176.
28.
SunJK, AielloLP, AbràmoffMD, et al.Updating the staging system for diabetic retinal disease. Ophthalmology, 2021; 128(4):490–493.
29.
JampolLM, TadayoniR, IpM. Need for a new classification of diabetic retinopathy. Retina, 2021; 41(3):459–460.
30.
ArrigoA, AragonaE, BandelloF. VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy. Ann Med, 2022; 54(1):1089–1111.
31.
Díaz-CoránguezM, LiuX, AntonettiDA. Tight junctions in cell proliferation. Int J Mol Sci, 2019; 20(23):5972.
32.
AielloLP, WongJ-S. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl, 2000; 77:S113–S119.
33.
ZhaoY, SinghRP. The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy. Drugs Context, 2018; 7:212532.
34.
ControlD, GroupCTR. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine, 1993; 329:977–986.
35.
WitmerA, VrensenG, Van NoordenC, SchlingemannR. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res, 2003; 22(1):1–29.
36.
ChanW-C, TsaiSH, WuA-C, et al.Current treatments of diabetic macular edema. In J Gerontol, 2011; 5(4):183–188.
37.
AielloLP, AveryRL, ArriggPG, et al.Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med, 1994; 331(22):1480–1487.
38.
AdamisAP, BrittainCJ, DandekarA, HopkinsJJ. Building on the success of anti-vascular endothelial growth factor therapy: A vision for the next decade. Eye (Lond), 2020; 34(11):1966–1972.
39.
BahrTA, BakriSJ. Update on the management of diabetic retinopathy: Anti-VEGF agents for the prevention of complications and progression of nonproliferative and proliferative retinopathy. Life, 2023; 13(5):1098.
40.
ChauhanMZ, RatherPA, SamarahSM, et al.Current and novel therapeutic approaches for treatment of diabetic macular edema. Cells, 2022; 11(12):1950.
41.
SmithCW, GuyerDR, D’AmicoDJ. Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am J Ophthalmol, 1992; 113(6):652–656.
42.
NetworkDRCR. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology, 2008; 115:1447–1459. e10.
43.
HallerJA, KuppermannBD, BlumenkranzMS, et al.Dexamethasone DDS Phase II Study Group. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol, 2010; 128(3):289–296.
StewartMW. Extended duration vascular endothelial growth factor inhibition in the eye: Failures, successes, and future possibilities. Pharmaceutics, 2018; 10(1):21.
46.
WellsJA, GlassmanAR, AyalaAR, et al.Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med, 2015; 372(13):1193–1203.
47.
ArevaloJF, Fromow-GuerraJ, Quiroz-MercadoH, et al.Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: Results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology, 2007; 114(4):743–750.
48.
BrownDM, NguyenQD, MarcusDM, et al.RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III trials: RISE and RIDE. Ophthalmology, 2013; 120(10):2013–2022.
49.
BrownDM, Schmidt-ErfurthU, DoDV, et al.Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology, 2015; 122(10):2044–2052.
50.
VirgiliG, ParravanoM, MenchiniF, EvansJR. Anti‐vascular endothelial growth factor for diabetic macular oedema. Cochrane Database of Syst Rev, 2014.
51.
CiullaTA, BrachaP, PollackJ, WilliamsDF. Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular edema in the United States. Ophthalmol Retina, 2018; 2(12):1179–1187.
52.
GlassmanAR, WellsJA, JosicK, et al.Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study). Ophthalmology, 2020; 127(9):1201–1210.
53.
BaumalCR, SørensenTL, KarcherH, et al.Efficacy and safety of brolucizumab in age‐related macular degeneration: A systematic review of real‐world studies. Acta Ophthalmol, 2023; 101(2):123–139.
54.
RegulaJT, Lundh von LeithnerP, FoxtonR, et al.Targeting key angiogenic pathways with a bispecific Cross MA b optimized for neovascular eye diseases. EMBO Mol Med, 2019; 11(5):e10666.
55.
LimJI, WellsJA, EichenbaumDA, et al.Efficacy, durability, and safety of faricimab in diabetic macular edema: 2-year results from the phase 3 YOSEMITE and RHINE trials. Investigative Ophthalmol Visual Sci, 2022; 63:3850–3850.
56.
BrownDM, BoyerDS, DoDV, et al.PHOTON Investigators. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet, 2024; 403(10432):1153–1163.
JorgeR, CostaRA, CalucciD, et al.Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina, 2006; 26(9):1006–1013.
59.
GrossJG, GlassmanAR, JampolLM, et al.Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA, 2015; 314(20):2137–2146.
60.
SivaprasadS, PrevostAT, VasconcelosJC, et al.CLARITY Study Group. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): A multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet, 2017; 389(10085):2193–2203.
61.
ArabiA, TadayoniR, AhmadiehH, et al.Update on management of non-proliferative diabetic retinopathy without diabetic macular edema; is there a paradigm shift? J Ophthalmic Vis Res, 2022; 17(1):108–117.
62.
IpMS, DomalpallyA, HopkinsJJ, et al.Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol, 2012; 130(9):1145–1152.
63.
ChatziralliI, TouhamiS, CicinelliMV, et al.Disentangling the association between retinal non-perfusion and anti-VEGF agents in diabetic retinopathy. Eye (Lond), 2022; 36(4):692–703.
64.
BrownDM, WykoffCC, BoyerD, et al.Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: Results from the PANORAMA randomized clinical trial. JAMA Ophthalmol, 2021; 139(9):946–955.
65.
MaguireMG, LiuD, GlassmanAR, et al.DRCR Retina Network. Visual field changes over 5 years in patients treated with panretinal photocoagulation or ranibizumab for proliferative diabetic retinopathy. JAMA Ophthalmol, 2020; 138(3):285–293.
66.
SivaprasadS, ElagouzM, McHughD, et al.Micropulsed diode laser therapy: Evolution and clinical applications. Surv Ophthalmol, 2010; 55(6):516–530.
67.
ShimuraM, YasudaK, NakazawaT, et al.Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology, 2003; 110(12):2386–2394.
68.
El AnnanJ, CarvounisPE. Current management of vitreous hemorrhage due to proliferative diabetic retinopathy. Int Ophthalmol Clin, 2014; 54(2):141–153.
69.
DugelPU, AbulonDJ, DimalantaR. Comparison of attraction capabilities associated with high-speed, dual-pneumatic vitrectomy probes. Retina, 2015; 35(5):915–920.
70.
HahnP, MigaczJ, O’ConnellR, et al.The use of optical coherence tomography in intraoperative ophthalmic imaging. Ophthalmic Surg Lasers Imaging, 2011; 42 Suppl(0):S85–S94.
71.
EmanuelliA, HolekampNM, LatkanyP, et al.Port delivery system with ranibizumab in the treatment of diabetic retinopathy without center-involved diabetic macular edema: Primary analysis results of the phase 3 Pavilion trial. Investigative Ophthalmol Visual Sci, 2023; 64:3754–3754.
72.
MauerM, ZinmanB, GardinerR, et al.Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med, 2009; 361(1):40–51.
73.
Group AS, Group AES. Effects of medical therapies on retinopathy progression in type 2 diabetes. New Eng J Med, 2010; 363:233–244.
74.
TingDSW, CheungGCM, WongTY. Diabetic retinopathy: Global prevalence, major risk factors, screening practices and public health challenges: A review. Clin Exp Ophthalmol, 2016; 44(4):260–277.
75.
WangB, WangF, ZhangY, et al.Effects of RAS inhibitors on diabetic retinopathy: A systematic review and meta-analysis. Lancet Diabetes Endocrinol, 2015; 3(4):263–274.
76.
DoDV, HanG, AbarigaSA, et al.Cochrane Eyes and Vision Group. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Rev, 2023; 2023(3).
77.
MeerE, BavingerJC, YuY, VanderBeekBL. Association of fenofibrate use and the risk of progression to vision-threatening diabetic retinopathy. JAMA Ophthalmol, 2022; 140(5):529–532.
78.
TanH, FuX, ChenY, et al.Hyperlipidemia and lipid-lowering therapy in diabetic retinopathy (DR): A bibliometric study and visualization analysis in 1993–2023. Heliyon, 2023; 9(10):e21109.
InvestigatorsFS. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet, 2005; 366:1849–1861.
81.
HuY, ChenY, DingL, et al.Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction. Proc Natl Acad Sci USA, 2013; 110(38):15401–15406.
82.
ChenQ, QiuF, ZhouK, et al.Pathogenic role of microRNA-21 in diabetic retinopathy through downregulation of PPARα. Diabetes, 2017; 66(6):1671–1682.
83.
LiY, RyuC, MunieM, et al.Association of metformin treatment with reduced severity of diabetic retinopathy in type 2 diabetic patients. J Diabetes Res, 2018; 2018:2801450.
84.
YiQ-Y, DengG, ChenN, et al.Metformin inhibits development of diabetic retinopathy through inducing alternative splicing of VEGF-A. Am J Transl Res, 2016; 8(9):3947–3954.
85.
AmbrosiusWT, DanisRP, GoffDC, et al.ACCORD Study Group. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: The ACCORD eye substudy. Arch Ophthalmol, 2010; 128(3):312–318.
86.
MatuszewskiW, Baranowska-JurkunA, Stefanowicz-RutkowskaMM, et al.The safety of pharmacological and surgical treatment of diabetes in patients with diabetic retinopathy—a review. J Clin Med, 2021; 10(4):705.
87.
SchernthanerG, GrimaldiA, Di MarioU, et al.GUIDE study: Double‐blind comparison of once‐daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest, 2004; 34(8):535–542.
88.
CosentinoF, GrantPJ, AboyansV, et al.ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J, 2020; 41(2):255–323.
89.
KanaiY, LeeW-S, YouG, et al.The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest, 1994; 93(1):397–404.
90.
InzucchiS, WannerC, HehnkeU, et al.Composite retinopathy outcome in patients treated with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel, 2019; 14:066.
91.
SharmaA, ParachuriN, KumarN, et al.Semaglutide and the risk of diabetic retinopathy—current perspective. Eye (Lond), 2022; 36(1):10–11.
92.
WangF, MaoY, WangH, et al.Semaglutide and diabetic retinopathy risk in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Clin Drug Investig, 2022; 42(1):17–28.
93.
BarkmeierAJ, HerrinJ, SwarnaKS, et al.Comparative Effectiveness of Glucagon-Like Peptide-1 receptor agonists, sodium-glucose Cotransporter 2 inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and sulfonylureas for sight-threatening diabetic retinopathy. Ophthalmol Retina, 2024; 8(10):943–952.
94.
KimYJ, ShinS, HanDJ, et al.Long-term effects of pancreas transplantation on diabetic retinopathy and incidence and predictive risk factors for early worsening. Transplantation, 2018; 102(1):e30–e38.
95.
GormanDM, Le RouxCW, DochertyNG. The effect of bariatric surgery on diabetic retinopathy: Good, bad, or both? Diabetes Metab J, 2016; 40(5):354–364.
96.
ChenY, LaybourneJP, SandinhaMT, et al.Medscape. Does bariatric surgery prevent progression of diabetic retinopathy? Eye (Lond), 2017; 31(8):1131–1139.
97.
ReynoldsEL, WatanabeM, BanerjeeM, et al.The effect of surgical weight loss on diabetes complications in individuals with class II/III obesity. Diabetologia, 2023; 66(7):1192–1207.
98.
CundiffDK, NiggCR. Diet and diabetic retinopathy: Insights from the Diabetes Control and Complications Trial (DCCT). MedGenMed, 2005; 7(1):3.
99.
RenC, LiuW, LiJ, et al.Physical activity and risk of diabetic retinopathy: A systematic review and meta-analysis. Acta Diabetol, 2019; 56(8):823–837.
100.
EinhornD, StewartDA, ErmanMK, et al.Prevalence of sleep apnea in a population of adults with type 2 diabetes mellitus. Endocr Pract, 2007; 13(4):355–362.
101.
AltafQA, DodsonP, AliA, et al.Obstructive sleep apnea and retinopathy in patients with type 2 diabetes. A Longitudinal Study. Am J Respir Crit Care Med, 2017; 196(7):892–900.
102.
García-SánchezA, Villalaín-RodesI, JaureguizarA, et al.Continuous positive airway pressure effect on progression of retinal disease in patients with Sleep Apnea and Nonproliferative diabetic retinopathy: A randomized clinical trial. Ann Am Thorac Soc, 2024; 21(1):102–113.
103.
KhananiAM, BoyerDS, WykoffCC, et al.Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): A prospective, two-year, multicentre phase 1 study. EClinicalMedicine, 2024; 67:102394.
104.
JiangJ, XuK, WangL, et al.Pharmacology study of a chimeric decoy receptor trap fusion protein on retina neovascularization by dual blockage of VEGF and FGF-2. Eur J Pharm Sci, 2018; 121:251–259.
105.
StefanssonE, LoftssonT, LarsenM, et al.DX-211 study group. Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: A randomized, double‐masked, vehicle‐controlled study. Acta Ophthalmol, 2023; 101(1):22–33.
106.
Crespo-GarciaS, FournierF, Diaz-MarinR, et al.Therapeutic targeting of cellular senescence in diabetic macular edema: Preclinical and phase 1 trial results. Nat Med, 2024; 30(2):443–454.
107.
PieramiciD, KlierS, RathmellJ, et al.Effect of patient baseline characteristics on response to UBX1325, a novel Senolytic candidate for patients with DME: BEHOLD Phase 2 Study 48 weeks follow-up. Investigative Ophthalmology & Visual Science, 2024; 65:1760–1760.
108.
KitaT, ClermontAC, MurugesanN, et al.Plasma kallikrein-kinin system as a VEGF-independent mediator of diabetic macular edema. Diabetes, 2015; 64(10):3588–3599.
109.
DugelPU, KhananiAM, BergerBB, et al.Phase 1 dose-escalation study of plasma kallikrein inhibitor THR-149 for the treatment of diabetic macular edema. Transl Vis Sci Technol, 2021; 10(14):28–28.
110.
HashidaN, NishidaK. Recent advances and future prospects: Current status and challenges of the intraocular injection of drugs for vitreoretinal diseases. Adv Drug Deliv Rev, 2023; 198:114870.
111.
ChongV, NguyenQD, SepahY, et al.HORNBILL: a phase I/IIa trial examining the safety, tolerability and early response of BI 764524 in patients with diabetic retinopathy and diabetic macular ischaemia—rationale, study design and protocol. Trials, 2022; 23(1):669.
112.
HeiselC, YousifJ, MijitiM, et al.APE1/Ref-1 as a novel target for retinal diseases. J Cell Signal, 2021; 2(2):133–138.
113.
SuD, PeposeJS, KelleyMR, et al.ZETA-1 Phase 2 Trial to determine the safety and efficacy of APX3330: a novel, Oral Ref-1 Inhibitor for the treatment of diabetic retinopathy. Investigative Ophthalmol Visual Sci, 2023; 64:3753–3753.
114.
NohM, KimY, ZhangH, et al.Oral administration of CU06-1004 attenuates vascular permeability and stabilizes neovascularization in retinal vascular diseases. Eur J Pharmacol, 2023; 939:175427.
115.
GroupLC, PreissD, LogueJ, et al.Design, recruitment and baseline characteristics of the LENS trial. Diabetic Med, 2024:e15310.
116.
PreissD, LogueJ, SammonsE, et al.Effect of fenofibrate on progression of diabetic retinopathy. NEJM Evid, 2024; 3(8):EVIDoa2400179.
117.
GretherU, FoxtonRH, GruenerS, et al.RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models. Front Pharmacol, 2024; 15:1426446.
